Cann Group AI Stock Analysis
Want to see AU:CAN full AI Analyst Report?
Cann Group (CAN) AI Stock Analysis
Cann Group
(ASX:CAN)
The score is weighed down primarily by weak financial performance: declining revenue, negative gross margins, persistent operating losses, and a headline profit that reflects one-off items rather than genuine earnings power. Management's restructuring — a roughly 78% reduction in debt, a return to positive equity, and cash burn cut to under A$2 million — meaningfully lowers near-term solvency risk, but comes alongside a materially smaller asset base. Valuation optics (a P/E near 0.3) are distorted by non-operating gains and offer no real support, and no dividend is paid. With no technical indicators available and the shares trading at a sub-cent level, risk and volatility are high. The decisive test remains whether Cann Group can restore revenue growth and positive gross margins before resources are exhausted.
Cann Group (CAN) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 5.81M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 0.3
- Beta (1Y)
- 0.50
- Revenue Growth
- -24.22%
- EPS Growth
- ―
- Country
- Australia
- Employees
- 40
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Cann Group Business Overview & Revenue Model
Company Description
Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of thera...
How the Company Makes Money
Cann Group makes money primarily by selling medicinal cannabis products and/or cannabis-derived inputs (such as dried flower and extracts) produced from its cultivation and manufacturing operations. Revenue is generated through supply arrangements wi...
Cann Group Financial Statement Overview
Summary
Cann Group remains a loss-making business in turnaround mode. Revenue fell roughly 24% to about A$8.6 million, gross profit was negative (margin near -94%), and operating income was around -A$12.0 million, meaning the company loses money on each dollar of product sold. The reported net profit of about A$20.3 million is driven by one-off, non-operating items rather than trading performance. Offsetting positives include a dramatic capital structure repair — debt cut from about A$75.8 million to A$16.8 million, equity restored from negative to A$28.6 million, and operating cash burn narrowed to about A$1.3 million from A$9.6 million. However, the asset base shrank from A$78.8 million to A$52.0 million, and the company has not produced positive operating cash flow in six years. Stabilisation, not yet recovery.
Income Statement
18Very NegativeBalance Sheet
40NegativeCash Flow
32Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.56M | 8.56M | 13.25M | 15.37M | 13.78M | 6.41M |
| Gross Profit | -8.06M | -8.06M | 5.15M | -21.75M | 20.63M | 11.24M |
| EBITDA | -5.42M | -6.16M | -8.94M | -35.54M | -24.63M | -24.36M |
| Net Income | 20.30M | 20.30M | -22.34M | -51.24M | -33.79M | -26.47M |
Balance Sheet | ||||||
| Total Assets | 51.99M | 51.99M | 78.79M | 92.77M | 129.47M | 139.66M |
| Cash, Cash Equivalents and Short-Term Investments | 490.00K | 490.00K | 10.00K | 1.64M | 765.00K | 1.91M |
| Total Debt | 16.84M | 16.84M | 75.84M | 72.47M | 60.97M | 47.16M |
| Total Liabilities | 23.39M | 23.39M | 81.56M | 78.85M | 70.20M | 54.76M |
| Stockholders Equity | 28.61M | 28.61M | -2.77M | 13.92M | 59.26M | 84.90M |
Cash Flow | ||||||
| Free Cash Flow | -1.74M | -1.74M | -9.80M | -17.69M | -25.94M | -65.60M |
| Operating Cash Flow | -1.33M | -1.33M | -9.64M | -15.19M | -22.84M | -20.43M |
| Investing Cash Flow | -406.00K | -406.00K | -157.00K | 1.18M | -28.00K | -45.16M |
| Financing Cash Flow | 2.22M | 2.22M | 8.17M | 14.77M | 21.71M | 64.41M |
Cann Group Peers Comparison
Overall Rating
AU:LGP51.5Neutral
AU:EXL43.2Neutral
AU:PKP39Underperform
AU:VIT39Underperform
AU:IDT34Underperform- AU:CAN33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:LGP | 52Neutral | AUD 49.68M | -15.22 | -1.67% | ― | 15.21% | -141.82% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:EXL | 43Neutral | AUD 2.72M | -0.59 | -50.35% | ― | -4.87% | -9.78% |
| AU:PKP | 39Underperform | AUD 20.09M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
| AU:VIT | 39Underperform | AUD 13.25M | -2.83 | -9.80% | ― | 5.74% | -222.22% |
| AU:IDT | 34Underperform | AUD 14.06M | -5.31 | -13.81% | ― | 5.93% | 66.32% |
| AU:CAN | 33Underperform | AUD 8.30M | 0.33 | 64.70% | ― | -24.22% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:EXL | Elixinol Wellness Ltd | 0.01 | 0.00 | 25.00% | |
| AU:LGP | Little Green Pharma Ltd. | 0.07 | -0.06 | -46.15% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.01 | -0.00 | -26.32% | |
| AU:IDT | IDT Australia Limited | 0.03 | -0.03 | -43.33% | |
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.04 | -68.33% |
Cann Group Corporate Events
Cann Group Swings to Profit as Debt Deal and Export Push Reset Its Balance Sheet
Cann Group has executed a major balance sheet and cost reset, turning a prior-year net deficiency into net assets of $29.1 million and reporting a statutory net profit after tax of $20.3 million. The restructuring included settling $70.6 million of b...
Cann Group appoints Stannards Audit as new company auditor
Cann Group Limited, an Australian medicinal cannabis producer, manufactures and researches cannabis medicines at a large-scale GMP facility near Mildura, Victoria. Through its Botanitech and Mallee Bloom brands, along with bulk and white-label channe...
Cann Group Redeems Convertible Notes, Streamlining Capital Structure
Cann Group Limited operates in the medicinal cannabis sector, focusing on the cultivation and production of cannabis-based products for regulated markets. The company is listed on the ASX under the ticker CAN and manages various forms of capital, inc...
Cann Group Secures $2m Increase to Private Credit Loan Facility
Cann Group Limited has agreed with its private credit lender to increase the total commitment under its existing loan facility by $2 million, less establishment fees, on the same terms as the current arrangement. The additional funding can only be dr...
Regal Partners exits substantial holding in Cann Group
Regal Partners Funds Management Pty Ltd and its associates have filed a notice stating they have ceased to be substantial holders in Cann Group Ltd. The change follows a series of share disposals in June 2026, culminating in the sale of more than 36...
Cann Group Seeks ASX Quotation for 19.2 Million New Shares
Cann Group Limited has applied for quotation on the ASX of 19,189,759 ordinary fully paid shares, with an issue date of 18 June 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, expan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026